Entecavir extended release - Aucta Pharmaceuticals

Drug Profile

Entecavir extended release - Aucta Pharmaceuticals

Alternative Names: Entecavir XR

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aucta Pharmaceuticals
  • Class Antivirals; Cyclopentanes; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 11 Aug 2017 Preclinical trials in Hepatitis B in China (PO)
  • 11 Aug 2017 Aucta Pharmaceuticals plans a phase I trial in Healthy volunteers in China (NCT03239353)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top